Compare Novartis with AKANKSHA FIN - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs OPTIEMUS INFRACOM - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS OPTIEMUS INFRACOM NOVARTIS/
OPTIEMUS INFRACOM
 
P/E (TTM) x 84.6 262.6 32.2% View Chart
P/BV x 2.6 7.9 33.6% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 NOVARTIS   OPTIEMUS INFRACOM
EQUITY SHARE DATA
    NOVARTIS
Mar-21
OPTIEMUS INFRACOM
Mar-21
NOVARTIS/
OPTIEMUS INFRACOM
5-Yr Chart
Click to enlarge
High Rs770207 371.2%   
Low Rs50115 3,362.4%   
Sales per share (Unadj.) Rs154.536.6 421.6%  
Earnings per share (Unadj.) Rs8.510.1 84.0%  
Cash flow per share (Unadj.) Rs13.410.6 126.2%  
Dividends per share (Unadj.) Rs10.000-  
Avg Dividend yield %1.60-  
Book value per share (Unadj.) Rs289.238.6 750.1%  
Shares outstanding (eoy) m24.6985.81 28.8%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x4.13.0 135.6%   
Avg P/E ratio x75.111.0 680.7%  
P/CF ratio (eoy) x47.510.5 453.1%  
Price / Book Value ratio x2.22.9 76.2%  
Dividend payout %118.10-   
Avg Mkt Cap Rs m15,6919,540 164.5%   
No. of employees `000NANA-   
Total wages/salary Rs m1,08548 2,255.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,8143,144 121.3%  
Other income Rs m3321,021 32.5%   
Total revenues Rs m4,1464,165 99.5%   
Gross profit Rs m267245 108.9%  
Depreciation Rs m12246 266.1%   
Interest Rs m77214 36.0%   
Profit before tax Rs m4001,007 39.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m191142 134.9%   
Profit after tax Rs m209865 24.2%  
Gross profit margin %7.07.8 89.8%  
Effective tax rate %47.814.1 339.2%   
Net profit margin %5.527.5 19.9%  
BALANCE SHEET DATA
Current assets Rs m9,2243,636 253.7%   
Current liabilities Rs m3,5731,593 224.3%   
Net working cap to sales %148.265.0 228.1%  
Current ratio x2.62.3 113.1%  
Inventory Days Days176114 154.7%  
Debtors Days Days371,738 2.1%  
Net fixed assets Rs m2,4801,178 210.6%   
Share capital Rs m123858 14.4%   
"Free" reserves Rs m7,0182,451 286.4%   
Net worth Rs m7,1413,309 215.8%   
Long term debt Rs m039 0.0%   
Total assets Rs m11,7034,813 243.1%  
Interest coverage x6.25.7 108.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.30.7 49.9%   
Return on assets %2.422.4 10.9%  
Return on equity %2.926.1 11.2%  
Return on capital %6.736.5 18.3%  
Exports to sales %9.31.6 570.4%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs m35451 691.9%   
Imports (cif) Rs mNA205 0.0%   
Fx inflow Rs m35451 691.9%   
Fx outflow Rs m974205 474.3%   
Net fx Rs m-621-154 402.3%   
CASH FLOW
From Operations Rs m-692-556 124.4%  
From Investments Rs m9522,226 42.8%  
From Financial Activity Rs m-368-1,357 27.1%  
Net Cashflow Rs m-109312 -34.8%  

Share Holding

Indian Promoters % 0.0 74.9 -  
Foreign collaborators % 70.7 0.0 -  
Indian inst/Mut Fund % 0.8 0.4 231.4%  
FIIs % 0.0 0.4 8.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.3 25.1 117.0%  
Shareholders   45,141 12,947 348.7%  
Pledged promoter(s) holding % 0.0 23.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   HCL INFOSYS    MMTC    SUNDRAM FASTENERS    FUTURE CONSUMER    STC INDIA    



Today's Market

Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 21, 2022 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS